Analyzing Cost of Revenue: Bio-Techne Corporation and BioCryst Pharmaceuticals, Inc.

Biotech Cost Trends: A Decade of Change

__timestampBio-Techne CorporationBioCryst Pharmaceuticals, Inc.
Wednesday, January 1, 2014106352000122000
Thursday, January 1, 20151449690001896000
Friday, January 1, 20161623640002699000
Sunday, January 1, 20171884620001702000
Monday, January 1, 2018210850000471000
Tuesday, January 1, 20192405150004101000
Wednesday, January 1, 20202554970001676000
Friday, January 1, 20212981820007264000
Saturday, January 1, 20223491030006594000
Sunday, January 1, 20233668870004661000
Monday, January 1, 2024389335000
Loading chart...

Igniting the spark of knowledge

Analyzing Cost of Revenue in the Biotech Sector

In the ever-evolving biotech industry, understanding cost structures is crucial for investors and stakeholders. This analysis focuses on Bio-Techne Corporation and BioCryst Pharmaceuticals, Inc., two prominent players in the field. Over the past decade, Bio-Techne has seen a consistent rise in its cost of revenue, growing by approximately 266% from 2014 to 2023. This trend reflects the company's expanding operations and increased production capabilities.

Conversely, BioCryst Pharmaceuticals has experienced more volatility. While its cost of revenue surged by over 5,800% from 2014 to 2021, it has since shown a decline, indicating potential shifts in production strategies or market conditions. Notably, data for 2024 is missing, suggesting a need for further investigation into recent developments.

These insights provide a window into the financial dynamics of biotech firms, highlighting the importance of cost management in sustaining growth.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025